- Home
- MHUA vs TLPH Comparison
MHUA vs TLPH Comparison
Compare MHUA & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- TLPH
- Stock Information
- Founded
- MHUA 1990
- TLPH 2005
- Country
- MHUA China
- TLPH United States
- Employees
- MHUA N/A
- TLPH N/A
- Industry
- MHUA Medical Specialities
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- MHUA Health Care
- TLPH Health Care
- Exchange
- MHUA Nasdaq
- TLPH Nasdaq
- Market Cap
- MHUA 15.6M
- TLPH 12.7M
- IPO Year
- MHUA 2022
- TLPH 2011
- Fundamental
- Price
- MHUA $0.32
- TLPH $0.67
- Analyst Decision
- MHUA
- TLPH Strong Buy
- Analyst Count
- MHUA 0
- TLPH 2
- Target Price
- MHUA N/A
- TLPH $4.50
- AVG Volume (30 Days)
- MHUA 897.2K
- TLPH 112.7K
- Earning Date
- MHUA 09-20-2024
- TLPH 03-05-2025
- Dividend Yield
- MHUA N/A
- TLPH N/A
- EPS Growth
- MHUA 29.93
- TLPH N/A
- EPS
- MHUA 0.37
- TLPH N/A
- Revenue
- MHUA $94,252,537.00
- TLPH $281,000.00
- Revenue This Year
- MHUA N/A
- TLPH N/A
- Revenue Next Year
- MHUA N/A
- TLPH N/A
- P/E Ratio
- MHUA $0.89
- TLPH N/A
- Revenue Growth
- MHUA N/A
- TLPH N/A
- 52 Week Low
- MHUA $0.25
- TLPH $0.50
- 52 Week High
- MHUA $1.47
- TLPH $1.61
- Technical
- Relative Strength Index (RSI)
- MHUA 37.70
- TLPH 55.43
- Support Level
- MHUA $0.30
- TLPH $0.55
- Resistance Level
- MHUA $0.35
- TLPH $0.64
- Average True Range (ATR)
- MHUA 0.03
- TLPH 0.06
- MACD
- MHUA 0.01
- TLPH 0.01
- Stochastic Oscillator
- MHUA 36.35
- TLPH 94.06
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.